Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment…
Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment…
More than 200,000 people in the United States are living with a chronic lymphocytic leukemia (CLL) diagnosis, and it is responsible for approximately 4,410 U.S. deaths each year. The treatment landscape for CLL has changed dramatically…
Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs). Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the…
The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a…
This Grand Rounds series focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will…
This is a live webcast addressing emerging therapeutic options for gastric, GEJ, and EAC cancers. This activity will address PD-L1 expression and its impact on treatment selection and sequencing, as well as the role of interprofessional…
This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics…